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Cardiovascular disease is the commonest cause of death worldwide and hypertension is 
the major risk factor;1 Mendelian hypertension elucidates mechanisms of blood pressure 
regulation. We identified six missense mutations in phosphodiesterase 3A (PDE3A) in six 
unrelated families with Mendelian hypertension and brachydactyly Type E (HTNB)2 by 
whole-genome sequencing. The syndrome features brachydactyly Type E (BDE), short 
stature, severe salt-independent but age-dependent hypertension, increased fibroblast 
growth rate, neurovascular contact at the rostral ventrolateral medulla, altered 
baroreflex blood pressure regulation, and death from stroke before age 50 when 
untreated.3,4 The PDE3A mutations resulted in gain-of-function, with increased cAMP-
hydrolytic affinity, and enhanced cell proliferation. The mutations increased protein 
kinase A (PKA)-mediated PDE3A phosphorylation. Mesenchymal stem cell-derived 
vascular smooth muscle cells (VSMC) and chondrocytes provided insights into the 
molecular pathogenesis of HTNB; PDE3A phosphorylation was enhanced, vasodilator-
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stimulated phosphoprotein (VASP) was diminished, while parathyroid hormone-related 
peptide (PTHrP) was dysregulated. We suggest that the identified PDE3A mutations 
cause the syndrome. VSMC-expressed PDE3A deserves scrutiny as a therapeutic target. 
 
All Mendelian hypertension syndromes described to date involve increased sodium 
reabsorption in the distal nephron.5 The sole exception is autosomal-dominant hypertension 
with BDE (HTNB, OMIM #112410), first reported in a Turkish kindred.2,6 HTNB was linked 
to chromosome 12p in six unrelated families.2,7,8 The locus accounts for a ~50 mm Hg mean 
blood pressure difference at age 50 years.2 The penetrance is 100% (Fig. 1a). Previously, we 
reported a rearrangement on chromosome 12p common to all families.8,9 A linkage study in 
Chinese hypertensive families without BDE coincided with the HTNB locus, supporting 
relevance to essential hypertension.10  
  Whole-genome sequencing of Turkish family members revealed a heterozygous 
missense mutation in PDE3A (Gene ID: 5139), a gene encoding a cGMP/cAMP 
phosphodiesterase with a prominent role in the heart, VSMC, oocytes and platelets.11 Re-
sequencing of all 48 affected persons in six unrelated families identified six independently 
clustered heterozygous missense mutations in exon 4 (Fig. 1a, b, 2a, Supplementary Table 1). 
The mutational amino acids 445, 447, and 449 belong to a highly conserved PDE3A domain 
(Supplementary Fig. 1).  
We detected none of the previously described chromosomal breakpoints on 
chromosome 12p12.2-12.1, perhaps due to high repetitive content in the breakpoint regions 
(Fig. 2a, Supplementary Table 2).8,9 Intra-familial variability was noted with an affected 
individual (VI/9, 145/77 mm Hg) showing only mild BDE with height (159 cm) in the 30th 
percentile compared to one of his severely affected cousins (142 cm, 1st percentile, VI/1; Fig. 
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2b).7 Magnetic resonance imaging revealed a posterior-inferior cerebellar artery (PICA) loop 
(Supplementary Fig. 2a-c).4 A haplotype analysis identified a novel recombination that 
reduced the linkage interval and eliminated an inversion common to all affected individuals in 
the six families (Fig. 2c).9 In contrast, the affected mother’s haplotype showed co-segregation 
with the more severe brachydactyly phenotype.  
           PDEs are involved during early stages of osteogenesis.12 PDE4D mutations have been 
associated with severe brachydactyly in acrodysostosis.13,14 In mice, Pde3a was expressed in 
the developing limbs, consistent with a role during chondrogenesis (Fig. 2d, Supplementary 
Fig. 3a, b). Chondrogenic downregulation of PTHLH encoding PTHrP was associated with 
BDE.15 We also observed PTHLH downregulation in chondrogenically induced fibroblasts 
from affected persons (Fig. 2e, Supplementary Fig. 3c).  
 We addressed the functional consequences of the identified PDE3A mutations in HeLa 
cells expressing the six mutations. Forskolin or L-arginine stimulated the adenylate or 
guanylate cyclases to enhance cellular cAMP or cGMP levels, respectively.16,17 We detected 
significantly reduced cAMP levels, consistent with gain-of-function mutations with no change 
in cGMP levels for the PDE3A mutations (Supplementary Fig. 4a, b). Three PDE3A 
isoforms, PDE3A1 (microsomal), PDE3A2 and PDE3A3 (microsomal and cytosolic), have 
been identified in human myocardium.18,19 PDE3A3 does not contain the sequence harboring 
the detected mutations. The predominant isoform in VSMC is PDE3A2.18,20 To directly 
elucidate the mutations’ effects, we compared the Michaelis-Menten kinetics of cAMP-
hydrolytic activity for recombinant T445N FLAG-tagged PDE3A1 and PDE3A1-WT and the 
tagged A2 isoforms purified from transfected cells (Fig. 3a, b, Supplementary Fig. 4d-k). The 
T445N mutation increased the affinity of both enzyme’s isoforms for cAMP (decreased KM) 
without affecting Vmax; this increase in affinity relative to the wildtype enzyme was enhanced 
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for both isoforms when cAMP-mediated signaling in transfected cells was stimulated by 
exposure to forskolin. IC50 measurements for milrinone, a PDE3 inhibitor, used to augment 
cardiac contractility and decrease vascular resistance in patients with heart failure,21,22 showed 
that higher concentrations of the inhibitor were necessary to inhibit both isoforms of the 
recombinant T445N PDE3A mutants (Fig. 3c, d), while the IC50 values for cGMP inhibition 
of cAMP-hydrolytic activity were nearly equivalent for wildtype and mutational enzyme 
(Supplementary Fig. 5).  
 We also used a luciferase vector under the control of a cAMP-responsive element to 
determine the effects of all six PDE3A mutations on cAMP-mediated signaling in cells.23 
Consistent with the observed gain-of-function effect and due to the resulting increased cAMP-
hydrolytic activity, expression of all six PDE3A mutations decreased luciferase expression 
compared to wildtype (Supplementary Fig. 6a-g).   
 We extracted mesenchymal stem cells (MSC) from two affected individuals with the 
mutation T445N (VI/9, VI/17). MSC were FACS-characterized and differentiated into 
adipocytes, osteocytes, and chondrocytes demonstrating their multilineage potential 
(Supplementary Fig. 7a, b).24 MSC-derived VSMC expressed smooth muscle actin alpha 
(SMAα), calponin, and transgelin at high levels (SM22α; Supplementary Fig. 7c). Because 
deleted murine Pde3a suppressed VSMC proliferation, indicating its importance during 
arteriogenesis and arterial remodeling25, we focused on the vascular relevance of the PDE3A 
mutations. In our earlier studies, we had observed an enhanced cell growth rate of affected 
person’s fibroblasts and hyperplastic blood-vessel walls, concerning the thickened VSMC 
layer.9,26 We hypothesized that the PDE3A mutations were responsible for enhanced mitosis 
and arterial remodeling. In HeLa proliferation assays with PDE3A full-length transfected 
constructs, as well as in T445N patient-derived VSMC, we determined higher mitotic rates. 
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Transfected wildtype PDE3A increased also cell growth compared to endogenous PDE3A 
(Fig. 3e, f, Supplementary Fig. 8). 
 Near the PDE3A mutations, the residues Ser428+438 can be phosphorylated by protein-
kinase C (PKC) or PKA, causing increased cAMP hydrolysis (Fig. 2a).18,27,28 Thus, we 
investigated phosphorylated PDE3A without and after exposure to PMA (to activate PKC) or 
forskolin (to yield activated PKA).29,30 The phosphorylation of mutational PDE3A1 and 
PDE3A2 at Ser428 and Ser438 was increased in PMA- and forskolin-treated HeLa cells, 
compared to endogenous and transfected wildtype PDE3A (Fig. Fig. 4a-e, Supplementary 
Fig. 9).19 In non-stimulated MSC and VSMC of the affected T445N patients, higher PDE3A 
Ser428 and Ser438 phosphorylation was detected (Fig. 4f, g). Inhibiting PKA or PKC showed 
that both kinases phosphorylated PDE3A Ser438 (Supplementary Fig. 10). We investigated 
whether or not the altered PDE3A phosphorylation could be attributed to a favored mRNA 
expression from the affected allele. We used pyrosequencing to dissect the allele usage and 
detected no differences (Supplementary Fig. 11). 
 Reduced phosphorylation of VASP at Ser157, mediated by PKA, has been linked to 
enhanced VSMC proliferation after angioplasty.31 Elevated full-length PTHrP enhanced 
neointimal proliferation, while the PTHrP peptide [1-36] inhibited VSMC proliferation.31,32 
We observed reduced VASP Ser157 phosphorylation and elevated PTHrP in PMA-stimulated 
HeLa cells expressing the mutational enzymes. VASP Ser157 phosphorylation was not greatly 
altered in forskolin-treated HeLa, most likely due to increased forskolin-induced cAMP levels 
that are sufficient for PKA activation despite hyperactive PDE3A (Fig. 4h). Moreover, 
increased expression of PTHrP full-length protein and decreased PTHrP peptide [1-36] were 
detected in affected persons’ cells (Supplementary Fig. 12).  
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  In a peptide-SPOT assay, we synthesized 30-mer peptides representing Ile421-Leu450 of 
PDE3A wildtype and the six mutations including alanine and asparagine replacements for 
Ser428+438 (Fig. 2a, 5a, Supplementary Fig. 13).33 The spotting of Ser438 or pre-phosphorylated 
serines at position 428 or 438, followed by PKA in vitro phosphorylation of Ser438, revealed 
significantly enhanced phosphorylation at the PDE3A Ser438 residue of the six mutants, 
confirming the previous results (Fig. 5a, b, Supplementary Fig. 14a-c). To further elucidate 
the increased phosphorylation signal at the pre-phosphorylated Ser438 residue (peptide lanes’ 7 
and 9), we examined whether PKA additionally phosphorylated further residues. Interestingly, 
the PKA signals increased even though Ser428 and Ser438 were substituted with alanine. This 
result could be due to increased phosphorylated Ser439 and Thr440, being close to Ser438 
(Supplementary Fig. 14d-f).  
 Finally, we substituted Ser428, Ser438, Ser439 and Thr440 with alanines and repeated the 
Michaelis-Menten kinetics of FLAG-tagged PDE3A1 and PDE3A2 WT versus the T445N 
mutant. The alanine substitutions led to reduced cAMP affinity. We measured enhanced KM 
values for the substituted isoforms, supporting the notion that the mutation-dependent 
enhanced phosphorylations at these sites were responsible for the increased cAMP affinity 
and hydrolysis (Fig. 5c, Supplementary Fig. 15).  
 We observed that PDE3A mutated at residues Ser428 and Ser438 was more extensively 
phosphorylated than wildtype PDE3A, and that PTHrP isoforms were dysregulated. Our 
results suggest that the increased PKA-phosphorylation at Ser438 and PKC-phosphorylation of 
Ser428, reported to increase PDE3A2 activity,27 may have contributed to the increase in the 
cAMP-hydrolytic activity of the mutational enzymes, leading to reduced cAMP levels and 
enhanced cell proliferation. This result would be consistent with the increased affinity of the 
T445N-mutant for cAMP we observed following exposure of transfected cells to forskolin 
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(Fig. 3a, b). Further important studies will aim to characterize the possible allosteric effects of 
these mutations on other phosphorylation sites that may modulate activity and on protein-
protein interactions involved in PDE3A function – for example, the interaction of PDE3A 
with phospholamban, SERCA2 and AKAP18 described in mouse heart.34,35   
 Augmented full-length PTHrP, decreased PTHrP peptide [1-36] and reduced VASP 
phosphorylation could additionally promote VSMC proliferation, leading to vessel wall 
hyperplasia. In our functional assays, we determined the gain-of-function effect for the 
PDE3A mutants. The observed IC50 values showed that a higher milrinone concentration was 
necessary to abrogate the increased PDE3A1 and PDE3A2 T445N cAMP hydrolysis. In 
luciferase assays, the inhibitors given alone were not sufficient to block the gain-of-function 
effect. These data are compatible with our previous results indicating that milrinone-induced 
forearm vasodilation in affected persons and controls were not significantly different.8  
 Our data strongly suggest that PDE3A mutations in HTNB are responsible for the 
hypertension by contributing to a general increase in peripheral vascular resistance (Fig. 
5d).2,26 The fact that PDE3 inhibition lowers blood pressure in hypertensive heart failure 
patients and in patients with pulmonary hypertension is consistent with this hypothesis.36 
cAMP inhibits myosin light-chain kinase (MLCK) through the phosphorylation of the latter 
by PKA, thereby causing VSMC relaxation. Dephosphorylation of myosin light chains by 
MLC phosphatase also produces relaxation.37 Enhanced PDE3A activity could, by lowering 
intracellular [cAMP] in VSMC, promote increased peripheral vascular constriction. 
Furthermore, increased VSMC proliferation could induce remodeling favoring hypertension, 
perhaps by vascular structural changes or neurovascular contact. Our studies of PDE3A 
mutants with increased activity showing enhanced mitosis are consistent with the observed 
decrease in VSMC proliferation when deleting PDE3A in an earlier study.25  
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 The milder BDE of subject VI/9 suggests that regulatory DNA elements or non-coding 
RNA of the excluded inversion region epigenetically trigger the BDE and short stature 
pathogenesis. We found that Pde3a, involved in murine chondrogenesis, could contribute to 
PTHLH downregulation that was associated with BDE.15,38 In chondrocytes, PTHrP is 
regulated by cAMP and transduces signals through the PTH/PTHrP receptor, activating 
adenylate cyclase for cAMP production.39,40 We suggest that increased cAMP hydrolysis 
could cause PTHrP downregulation through a regulatory feedback loop (Fig. 5d). 
 In conclusion, we have identified independently clustered PDE3A mutations in HTNB 
individuals, exhibiting a gain-of-function effect on cAMP hydrolysis. We found evidence for 
mechanisms mediating VSMC hyperplasia and increased peripheral vascular resistance. The 
functional consequences of the PDE3A mutations in animal models will result in further 
insight into the normal and pathogenic vascular and skeletal development.  
 
Methods summary 
 
 We studied six unrelated families. After approval by the ethics committee (Charité 
Medical Faculty, Berlin) and written, informed consent, we obtained skin fibroblasts from 6 
affected persons (3 ♂, 3 ♀) and 8 controls (5 ♂, 3 ♀) from the Turkish kindred; mean age was 
37.7±0.4 years. We extracted mesenchymal stromal cells (MSC) from two affected Turkish 
males (VI/9, 17 years and VI/17, 12 years) and two non-affected and non-related (♂: 15, ♀: 
59 years) controls. Additional methods are described in the supplements.  
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Figures 
 
Figure 1. Pedigrees and PDE3A missense mutations in six unrelated families with autosomal-
dominant hypertension with brachydactyly type E (HTNB). 
(a) The genomes of the Turkish family members IV/6, IV/7, V/14 and V/30 were sequenced. 
DNA from all affected and non-affected Turkish family members was used for PDE3A Sanger 
sequencing. The asterisks in the pedigrees of the other families indicate PDE3A re-sequencing 
of family members. In all affected persons (black symbols) a PDE3A mutation was found in 
comparison to their non-affected related family members (white symbols), demonstrating 
complete penetrance in all families. The nuclear family of V/6+7 and VI/7-9 was used for 
haplotype analysis. X-rays of VI/1 and VI/9 are shown in Figure 2b. MSC were extracted 
from VI/9 and VI/17. (b) Six different PDE3A missense mutations introduced amino-acid 
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changes at positions 445, 447, and 449; total number of samples analyzed; AFF = affected 
persons, NON = non-affected controls 
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Figure 2. The linkage interval of HTNB and Pde3a, and PTHLH in chondrogenesis.  
 (a) The linkage interval of all families (grey bar) with flanking SNPs on chromosome 
12p12.2-12.1 and the previously described inversion (INV) is shown (human genome 
assembly hg19). The red bar shows the linkage interval of a hypertensive boy with mild BDE 
and near-average height for age (VI/9, panel c) with all annotated RefSeq genes. The peptide 
sequence of PDE3A exon 4 harboring the mutations (amino acids 445, 447 and 449) and the 
phosphorylation sites Ser428+438 near the mutations is shown. The sequence of PDE3A Iso421-
Leu450 (30-mer peptide) was used for peptide SPOT assays (Fig. 5 and Supplementary Fig. 13, 
14). (b) Mild BDE of VI/9 and of his cousin VI/1 that was far more severe. (c) A haplotype 
analysis of the Turkish nuclear family identified a novel recombination excluding the 
inversion from linkage in VI/9 (black square), compared to his mother V/6 (black circle). (d) 
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The chondrogenic Pde3a expression in developing mice at 12.5d and 13.5d was studied by 
RNA in situ hybridizations. Pde3a was expressed in domains involved in digit formation. (e) 
The BDE-associated PTHLH was downregulated in chondrogenically-induced fibroblasts 
from 6 age and gender-matched affected persons versus 8 non-affected controls (mean±SEM, 
Wilcoxon-Mann-Whitney rank sum test, p = 0.022).  
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Figure 3. Michaelis-Menten kinetics and IC50 measurements, and CFSE proliferation assays. 
HeLa cells were transiently transfected to express FLAG-tagged wildtype (WT) or the T445N 
PDE3A mutation. Recombinant PDE3A1 or PDE3A2 proteins were purified via their FLAG-
tags. (a) In Michaelis-Menten kinetics of PDE3A1 and (b) of PDE3A2, Vmax and KM revealed 
that the T445N mutation purified from non-stimulated and forskolin-stimulated cells 
displayed increased cAMP-affinity compared to PDE3A WT (n = 3). (c) For the inhibitor 
milrinone, the IC50 for PDE3A1 WT was 1.12x10-4 µM, in contrast to 0.234 µM for the 
T445N mutant (n = 3). (d) For PDE3A2 WT the IC50 for milrinone was 0.0034 µM, in 
comparison to 1.242 µM for PDE3A2 T445N (n = 2). (e) A proliferation assay elucidated 
increased mitosis for all the six PDE3A mutations compared to PDE3A wildtype after 
expression in HeLa cells (mean±SEM of n = 3, Wilcoxon-Mann-Whitney rank sum test, 
p<0.01, p<0.05). The difference in cell numbers between mutational PDE3A and wildtype 
cells was modest 6.2 % and maximum 9.5 %. (f) Proliferation assay of two patient-derived 
VSMC (AFF) and two controls (NON). The patients’ VSMC proliferated faster than the 
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controls, doubling time (td) for NON was 36.3 h and 30.2 h for AFF (means±SEM of n = 3, 
Wilcoxon-Mann-Whitney test, p = 0.05). The functional assays in Figure 3 were biological 
replicates. 
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Figure 4. PDE3A Ser428+438 phosphorylation in HeLa cells transfected with full-length 
PDE3A, in MSC and in MSC-derived VSMC. 
 (a) In densitometrical Western blotting quantifications of PMA-stimulated, and (b) forskolin-
treated HeLa, significant differences between transfected wildtype (WT) and each mutational 
PDE3A at Ser428 and Ser438 were determined after normalization to β-tubulin. PDE3A 
mutational signal differences are shown as fold changes relative to the expression of 
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transfected PDE3A WT. The phosphorylation of mutational PDE3A1 and PDE3A2 (mt) were 
increased compared to wildtype (WT), (mean±SEM of n = 3, two-tailed Wilcoxon-Mann-
Whitney test, ** p<0.01, * p<0.05). (c) HeLa cells transiently expressing the six PDE3A 
mutations were non-stimulated, (d) stimulated with PMA to induce PKC, or (e) treated with 
forskolin to activate PKA. Detection of expression of co-transfected Renilla luciferase 
confirmed equal transfection conditions; β-tubulin was loading control. Anti-PDE3A 
antibodies detected the isoforms A1 and A2. Experimental and variation differences in 
phosphorylation were detected upon quantification and normalization to the loading control 
and are summarized in the scatter plots of panel a and b; single values are given in 
Supplemental Fig. S10. (f) Differences in phosphorylated PDE3A residues Ser428 and (g) 
Ser438 were documented between two non-affected controls (NON) and two affected persons 
(AFF) using semi-quantitative immuno-fluorescence. The pseudo-color spectrum indicates 
signal intensities from low (black) to high (red). PDE3A was highly phosphorylated in the 
T445N AFF compared to NON, in MSC and VSMC. Scale bar = 50 µm. (h) PMA and 
forskolin stimulation of transfected HeLa. PMA stimulation caused reduced PKA-mediated 
VASP Ser157 phosphorylation and higher PTHrP expression in cells expressing the PDE3A 
mutants. The expression of non-phosphorylated VASP did not change. Western blots for 
quantifications were biological replicates from three independent experiments. 
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Figure 5. Peptide SPOT assay of the PDE3A mutation T445N. 
(a) PDE3A wildtype (WT) and PDE3A T445N mutant peptides representing Iso421-Leu450 
were spot-synthesized (sequences in Supplementary Fig. 13a). Ser428+438 were replaced by 
alanine (A) and asparagine (D) as indicated. For visual simplicity, signals of PDE3A wildtype 
versus PDE3A T445N mutation are shown; remaining mutations’ peptide spots are shown in 
Supplementary Fig. 13b. PKA phosphorylation of pre-phosphorylated (pS) Ser428 showed 
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higher serine (S) Ser438 phosphorylation of the T445N mutant (lane 6). Pre-phosphorylated 
Ser438 and subsequent PKA incubation also caused enhanced phosphorylation signals of all 
PDE3A mutations (lane 7 and 9; Supplementary Fig. 13b). (b) Densitometrical quantification 
of peptide spots of all mutants. The signals of lanes 6, 7 and 9 showed significantly enhanced 
phosphorylation after PKA incubation (mean±SEM of biological replicates n = 3, two-tailed 
Wilcoxon-Mann-Whitney rank sum test, ** p<0.01, * p<0.05). (c) Michaelis-Menten (MM) 
kinetics of FLAG-tagged PDE3A1 and PDE3A2 wildtype (WT) and T445N in comparison to 
FLAG-tagged PDE3A isoforms substituted (sub.) with alanines at position 428, 438, 439 and 
440. The substitutions led to a decrease in the cAMP affinity and cAMP hydrolysis 
(mean±SD of biological replicates n = 3). The data shown are the ratios of phosphorylated 
PDE3A wildtype (WT) or T445N versus their substituted isoforms in percent. Western 
blotting validated equal PDE3A amounts during functional MM-kinetics and diminished 
Ser438phosphorylation upon alanine substitutions. (d) Compendious scheme for the PDE3A 
involvement in VSMC and chondrocytes. In VSMC, the myosin light-chain kinase (MLCK) 
and the myosin light chain phosphatase (MLCP) act in concert to phosphorylate and 
dephosphorylate the myosin light chain (MLC) for vascular contraction and relaxation, 
respectively.37 PKA and protein kinase G (PKG) activate VASP by phosphorylation of Ser157 
and Ser239, respectively.41 Reduced VASP Ser157 phosphorylation and higher PDE3A activity 
were associated with enhanced VSMC proliferation that accounts for vessel wall 
hyperplasia.31 Full-length PTHrP stimulated whilst PTHrP [1-36] repressed the VSMC 
proliferation.32 CREB binding to the PTHLH promoter regulates PTHLH expression in a 
cAMP-dependent manner. The encoded protein PTHrP transduces signals through the PTH1R 
(PTH/PTHrP) receptor in chondrocytes and activates Gs-α, thereby stimulating the adenylate 
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cyclase (AC) to produce cAMP.39 Since PDE3A hydrolyses cAMP, PKA is cAMP-
dependently regulated and activates CREB, which in turn regulates the PTHLH expression.40  
 
